Supporting Information: Fig. S2



Fig. S2. Biodistribution and therapeutic results of α-RIT using ^{211}At-trastuzumab in the subcutaneous xenograft mouse models. (a) Biodistribution of ^{211}At-trastuzumab in mice with a subcutaneous xenograft of N87. Uptakes (%ID/g) of ^{211}At in the tumor and other

organs at 1, 3, 6, 12, and 24 h after i.v. injection of ^{211}At-trastuzumab (0.5 MBq). Four mice were used at each time point. Mean ± SD. (b) Relative tumor volume in each mouse enrolled in this study. The tumor volume before the treatment was considered 100%. Six mice were enrolled in each of the treatment groups except in the trastuzumab group (seven mice). PBS (Control). Mean ± SD ($P < 0.05$, *vs. Control, †vs. Tras.). (c) Kaplan-Meier survival curves of mice ($P < 0.05$, *vs. Control, †vs. Tras.). (d) Body weights of mice after treatment. (e) Numbers of white blood cells of the mice after treatment. Plots in (b), (d), and (e) were interrupted when any mouse enrolled in a group reached the endpoint. Data in (d) and (e) are presented as the mean ± SD.